USP22 and pancreatic ductal adenocarcinoma: Interestingly, research from the Stanger lab (33) demonstrated that loss of USP22 in pancreatic ductal adenocarcinoma led to enhanced NK cell infiltration, suggesting that additional mechanisms may influence the impact of USP22 targeting on NK cell immunity, which deserve extensive future studies to explore the underlying cellular and molecular mechanisms.